Pieter Boelhouwer is a Partner and Managing Director of Strategy and Operations at RA Capital Management. Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. He holds a MS from Northeastern University and a BA from Hamilton College. He holds a BS in Computer Science from Northeastern University. Bracketts primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Merediths previous experience includes Medical Education Researcher and Medical Scribe positions at BMC Global Inc. and Longwood Pediatrics, respectively. While at Orbimed, he drove proprietary deal sourcing, diligence, negotiation, and investment decisions for growth stage companies and determined valuation ranges for companies and products with a focus on technology platform value, commercial potential, and binary catalysts such as clinical and regulatory milestones. Cameron is a Senior Research Assistant at RA Capital Management. He is a co-author on over 140 publications and is a co-inventor on 40 issued U.S. patents. He previously served as the CFO of Research Alliance Corp I before its merger with Point Biopharma and served on the boards of Research Alliance Corp I and Research Alliance Corp II. Peyman Hosseinchi is an Associate within the TechAtlas division of RA Capital Management. Michael Sherman is a Venture Partner at RA Ventures. He is also the co-founder of multiple biotechnology companies including HiFiBiO and Design Pharmaceuticals. Gunes conducts due diligence on biotechnology companies at RA Capital. Peter Pan Is The Real Villain: Disney Supports The Evil Peter Pan Theory Priscillas primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. At Ra Pharma, Alonso held various leadership roles where he initiated and led the scientific efforts for the company in multiple preclinical and clinical programs; working in a wide set of therapeutic areas and using different molecular modalities. Michael Varnum is a Research Assistant at RA Capital Management. TJ has a BS in Business Administration with a concentration in Accounting from Northeastern University. MarketScreener: Created by Investors for Investors! Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. Brian Lewandowski is an Analyst on the Investment Team at RA Capital Management. Daniel holds both a BS and MS degree in Microbiology and Immunology from McGill University. Ally Boertzel is an Executive Assistant at RA Ventures (RAVen). He holds a BS in Computer Science from The University of California, San Diego, and worked previously as a Software Engineer at IBM and Fidelity Investments. In this role he works closely with the RA Ventures team to evaluate and incubate early stage therapeutic programs. During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the companys first product, and execution of a transformational, multi-billion collaboration. She is on the Steering Committee for No Patient Left Behind, a non-profit focused on reforming American healthcare to make medicines affordable to patients and promote innovation. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. Previously, Zach covered the neurology, ophthalmology, and dermatology landscapes. Mario held a Project Director position at BARDA working on Universal Flu Vaccine and leading the technical selection and completion of multiyear/multi million vaccine development programs. Raj holds a BA from Cornell University, where he majored in Chemistry. Laura works on new company creation and early-stage investments, and serves as a Board Director for Be Biopharma, Expansion Therapeutics, Hemab, and Aliada Therapeutics. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Peter Kolchinsky's Post - LinkedIn Jesse Chen is an EIR at RA Capital. As the first and founding member of Kymeras scientific team, Jesse was responsible for building the companys industry-leading targeted protein degradation platform and pipeline, and he helped secure the companys Series A and B financings as well as a partnership with Vertex. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University. James primary responsibilities are to advise RA Capital on public and private investments, coordinate with portfolio companies regarding deal structures and terms, and provide counsel and oversight on regulatory matters. Matt comes to RA from Localytics where he served as a Senior Software Engineer for the past two years. Many of the assets he contributed to within HNDC have been out-licensed to various Cambridge and Boston-based startups and biotech firms for further development. Christy is a Senior Associate with the TechAtlas division of RA Capital Management. Peter Kolchinsky - Managing Partner - CrunchBase Tyler Kowalski is an InteractiveDesigner at RA Capital Management. Rez brings to RA over 20 years of experience working in the life-science industry. James was a post-doctoral fellow at Massachusetts Institute of Technology and University of California, Berkeley. While at Tamarack, he managed coverage expansion into commercial-stage biotech, pharma, and specialty pharma sectors.

Robert Shapiro And Ben Shapiro, Statement Of Damages Sample Nj, Articles P